GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (MEX:SOBI N) » Definitions » Tariff Resilience Score

Swedish Orphan Biovitrum AB (MEX:SOBI N) Tariff Resilience Score : 8/10 (As of Jul. 04, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Swedish Orphan Biovitrum AB Tariff Resilience Score?

Swedish Orphan Biovitrum AB has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Swedish Orphan Biovitrum AB has Swedish Orphan Biovitrum AB has a strong global presence with diversified markets. It benefits from industry-specific exemptions and has shown resilience to past tariff changes.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Swedish Orphan Biovitrum AB might have Highly Resilient.

Competitive Comparison of Swedish Orphan Biovitrum AB's Tariff Resilience Score

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's Tariff Resilience Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Tariff Resilience Score falls into.


;
;

Swedish Orphan Biovitrum AB  (MEX:SOBI N) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Swedish Orphan Biovitrum AB Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (MEX:SOBI N) » Definitions » Tariff Resilience Score
Comparable Companies
OSTO:BIOG B OSTO:CRNO B OSTO:EQL OSTO:DICOT OSTO:CINPHA OSTO:ORX OSTO:ENZY OSTO:MOB OSTO:NANEXA XSAT:ACUC ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
SWOBY:USA BIOVF:USA SOBI:Sweden 1SOBI:Italy SOBIs:UK 0MTD:UK B6E:Germany
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Website
https://www.sobi.com
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines